News » GW Cancer Center Taps Dr. Jianqing Lin and Dr. Harold Frazier to Lead the...

GW Cancer Center Taps Dr. Jianqing Lin and Dr. Harold Frazier to Lead the Genitourinary Oncology Multidisciplinary Program

The George Washington University (GW) Cancer Center is pleased to announce that Jianqing Lin, M.D., associate professor of medicine and physician in the Division of Hematology/Oncology, and Harold Frazier, II, M.D., FACS, professor of urology, have been tapped to co-lead GW Cancer Center's newly established Genitourinary (GU) Oncology Multidisciplinary Program. Lin and Fraizer will encourage and foster collaborations between oncologists, urologists, radiologists, radiation oncologists, pathologists, population scientists, and basic scientists to enhance clinical and translational research in the areas of prostate, urothelial, kidney, penile, and testicular cancers.

"This is a critical time of growth for the GW Cancer Center and we are pleased that Dr. Lin and Dr. Frazier have agreed to lead in this area of strength. The GU Oncology Multidisciplinary Program will provide more opportunities for our GU care and research teams to work closely on identifying new strategies that will improve the lives of our patients," said Eduardo Sotomayor, M.D., inaugural director of the GW Cancer Center.

Lin, who recently joined the GW Cancer Center from the Department of Medical Oncology at Thomas Jefferson University in Philadelphia, was a key member of its GU Malignancies Program. He led the high dose interleukin-2 program and was the principal Investigator of several investigator initiated phase I/ II clinical trials using novel targeted agents and combinatorial strategies including checkpoint blockade antibodies that had resulted in several peer-reviewed manuscripts. Lin has particular expertise in the area of early phase clinical trials, cancer immunotherapy and the latest systemic treatment for prostate, bladder, kidney, and testicular cancer. He currently serves as member of ECOG/ACRIN Genitourinary Oncology Committee.

Lin earned his M.D. degree at Zhejiang Medical University in China and a MA degree at Marshall University in West Virginia. He performed a research fellowship at Boston Children's Hospital/Harvard Medical School. Lin then pursued training in internal medicine at Tufts University, followed by a fellowship in medical oncology at Johns Hopkins University. At Hopkins, he continued with his focus in GU malignancies. He is widely published author on the topic of prostate cancer, including a report of several clinical trials in prostate cancer.

Frazier is the co-founder of the Urologic Robotic Surgery Program at GW Hospital, a program that is the regional leader in this type of surgery and has performed over 4,000 robotic cases. Frazier is considered a pioneer in this technology as well as an outstanding mentor who has trained over 80 surgeons in the use of the da Vinci Surgical System. Frazier previously served as chief of urology with the Mid-Atlantic Permanente Medical Group, residency program director and assistant chairman of urology at the National Naval Medical Center in Bethesda, and an adjunct professor of surgery with The Uniformed Services University of the Health Sciences. While serving in the U.S. Navy, he also worked at the Walter Reed Army Medical Center, and served as a urologic consultant to the White House Medical Office and the Congressional Medical Office. Frazier has contributed many publications in top tier journals in his specialty. He received his medical degree with honors from Dartmouth Medical School, where he was elected a member of the Alpha Omega Alpha Honor Medical Honor Society. He completed his internship and residency at the National Naval Medical Center and received subspecialty training as a fellow in urologic oncology at Duke University Medical Center.

"Under the leadership of Dr. Lin and Dr. Frazier, this program is certain to have success. The formation of the GU Oncology Multidisciplinary Program is an important step as we enhance our research agenda in all forms of genitourinary cancers and provide the most cutting-edge therapies to our patients," said Thomas Jarrett, M.D., chair of the Department of Urology.